Olema Pharmaceuticals (OLMA)
Market Price (4/15/2026): $16.29 | Market Cap: $1.5 BilSector: Health Care | Industry: Biotechnology
Olema Pharmaceuticals (OLMA)
Market Price (4/15/2026): $16.29Market Cap: $1.5 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -34% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. | Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -179 Mil Stock price has recently run up significantly12M Rtn12 month market price return is 301% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -15% High stock price volatilityVol 12M is 162% Key risksOLMA key risks include [1] binary Phase 3 results for its lead drug palazestrant, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -34% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -179 Mil |
| Stock price has recently run up significantly12M Rtn12 month market price return is 301% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -15% |
| High stock price volatilityVol 12M is 162% |
| Key risksOLMA key risks include [1] binary Phase 3 results for its lead drug palazestrant, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Profit-taking after significant stock appreciation. Olema Pharmaceuticals' stock had surged over 240% in the year leading up to Q4 2025, reaching highs of approximately $36.26. Following this substantial rally, the stock experienced a pullback of roughly 44% from its Q4 2025 highs, suggesting investors engaged in profit-taking or reassessed near-term risk.
2. Concerns over future financing needs and potential dilution. Despite a robust cash position of $505.4 million at the end of 2025, bolstered by a $218.5 million follow-on offering in November, the company announced a new shelf registration for up to $71.82 million in common stock, which raised concerns about potential dilution among investors. Additionally, Olema Pharmaceuticals anticipates requiring approximately $550 million in additional financing through 2040, with its current cash runway only extending into 2027, signaling significant future capital needs.
Show more
Stock Movement Drivers
Fundamental Drivers
The -34.8% change in OLMA stock from 12/31/2025 to 4/14/2026 was primarily driven by a -6.2% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 12312025 | 4142026 | Change |
|---|---|---|---|
| Stock Price ($) | 25.00 | 16.30 | -34.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 86 | 91 | -6.2% |
| Cumulative Contribution | 0.0% |
Market Drivers
12/31/2025 to 4/14/2026| Return | Correlation | |
|---|---|---|
| OLMA | -34.8% | |
| Market (SPY) | -5.4% | 12.2% |
| Sector (XLV) | -3.9% | 25.7% |
Fundamental Drivers
The 66.5% change in OLMA stock from 9/30/2025 to 4/14/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 9302025 | 4142026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.79 | 16.30 | 66.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 85 | 91 | -6.4% |
| Cumulative Contribution | 0.0% |
Market Drivers
9/30/2025 to 4/14/2026| Return | Correlation | |
|---|---|---|
| OLMA | 66.5% | |
| Market (SPY) | -2.9% | -4.8% |
| Sector (XLV) | 7.4% | 14.4% |
Fundamental Drivers
The 333.5% change in OLMA stock from 3/31/2025 to 4/14/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 3312025 | 4142026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.76 | 16.30 | 333.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 75 | 91 | -17.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
3/31/2025 to 4/14/2026| Return | Correlation | |
|---|---|---|
| OLMA | 333.5% | |
| Market (SPY) | 16.3% | 0.9% |
| Sector (XLV) | 3.3% | 16.7% |
Fundamental Drivers
The 369.7% change in OLMA stock from 3/31/2023 to 4/14/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 3312023 | 4142026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.47 | 16.30 | 369.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 40 | 91 | -56.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
3/31/2023 to 4/14/2026| Return | Correlation | |
|---|---|---|
| OLMA | 369.7% | |
| Market (SPY) | 63.3% | 10.6% |
| Sector (XLV) | 20.4% | 18.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| OLMA Return | -81% | -74% | 473% | -58% | 329% | -36% | -67% |
| Peers Return | -8% | -31% | -24% | -16% | -9% | 6% | -61% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 81% |
Monthly Win Rates [3] | |||||||
| OLMA Win Rate | 25% | 33% | 75% | 25% | 58% | 50% | |
| Peers Win Rate | 42% | 48% | 42% | 48% | 50% | 65% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| OLMA Max Drawdown | -82% | -78% | 0% | -60% | -48% | -46% | |
| Peers Max Drawdown | -42% | -53% | -59% | -40% | -67% | -16% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ARVN, VERU, ZYME, KPTI, CLDX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/14/2026 (YTD)
How Low Can It Go
| Event | OLMA | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -96.2% | -25.4% |
| % Gain to Breakeven | 2529.4% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
Compare to ARVN, VERU, ZYME, KPTI, CLDX
In The Past
Olema Pharmaceuticals's stock fell -96.2% during the 2022 Inflation Shock from a high on 2/19/2021. A -96.2% loss requires a 2529.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Olema Pharmaceuticals (OLMA)
AI Analysis | Feedback
Here are 1-2 brief analogies for Olema Pharmaceuticals:
An early-stage Seagen for women's cancer treatments.
A developing Incyte specializing in women's cancer drugs.
AI Analysis | Feedback
- OP-1250: A lead drug candidate in Phase 1/2 clinical trials, developed as an estrogen receptor antagonist and selective ER degrader for the treatment of certain types of breast cancer.
AI Analysis | Feedback
Olema Pharmaceuticals, Inc. (OLMA) is a clinical-stage biopharmaceutical company. As described, its lead product candidate, OP-1250, is currently in Phase 1/2 clinical trials. This means the company is primarily engaged in the discovery and development of therapies and has not yet commercialized any products.
Therefore, Olema Pharmaceuticals does not currently have major customers that purchase its products or services. Its activities are focused on research and development to bring its drug candidates through clinical trials and regulatory approval.
AI Analysis | Feedback
nullAI Analysis | Feedback
Sean Bohen, M.D., Ph.D. President and Chief Executive Officer and Interim Principal Financial OfficerDr. Bohen was appointed President and Chief Executive Officer of Olema Pharmaceuticals in September 2020 and led the company's IPO in November 2020. A medical oncologist and biochemist by training, he previously served as Executive Vice President of Global Medicines Development and Chief Medical Officer at AstraZeneca for approximately five years and led early development at Genentech for about 13 years.
Shane Kovacs Former Chief Operating and Financial Officer
Mr. Kovacs departed Olema Pharmaceuticals as Chief Operating and Financial Officer on January 30, 2026, to pursue new opportunities, but will continue in a consulting role with the company through August 1, 2026. He joined Olema in 2020 and contributed to guiding the company's lead product candidate, palazestrant, through late-stage clinical development, building the finance team, and establishing a strong capital position.
David Myles, Ph.D. Chief Discovery and Non-Clinical Development Officer
Naseem Zojwalla, M.D. Chief Medical Officer
Shawnte Mitchell, J.D. Chief Legal Officer and Corporate Secretary
AI Analysis | Feedback
The key risks to Olema Pharmaceuticals (OLMA) are primarily associated with the inherent uncertainties of clinical-stage biopharmaceutical development, particularly concerning its lead product candidate, palazestrant (OP-1250).
1. Clinical Trial Failure and Regulatory Approval Risk
Olema Pharmaceuticals is a clinical-stage company with no products currently approved for commercial sale, making its value heavily dependent on the successful progression and eventual regulatory approval of its lead drug candidate, palazestrant. The company's future is significantly tied to the outcomes of its clinical trials, including the pivotal Phase 3 OPERA-01 study. A recent example highlighting this risk was the substantial decline in OLMA's stock (falling by -25.75% to -41%) following the disappointing results of a competitor's (Roche's giredestrant) similar drug in a late-stage Phase 3 clinical trial. This event raised concerns among investors about the entire class of selective estrogen receptor degraders (SERDs) that Olema is developing, even though palazestrant is a distinct molecule. Any setbacks in these trials, such as lack of efficacy, safety concerns, or failure to meet primary endpoints, could severely impact the company's prospects and stock price.
2. Competition
Olema operates in a competitive landscape, contending with other developers of oral SERDs and established endocrine therapies for breast cancer. The market share for palazestrant, if approved, will depend on its performance in pivotal trials, subsequent regulatory approvals, and its pricing compared to existing standards of care. The failure of a competitor's drug, as seen with Roche's giredestrant, underscores the intense competition and the potential for negative sentiment to impact the entire drug class, regardless of direct product differences. Olema must differentiate palazestrant in terms of efficacy and safety to succeed against both current treatments and other emerging therapies.
3. Capital Needs and Operating Losses
As a clinical-stage biopharmaceutical company without approved products or product revenue, Olema Pharmaceuticals consistently incurs significant net losses and requires substantial additional capital to fund its operations and ongoing research and development programs. Analysts anticipate widening losses as the company advances its lead drug candidate through late-stage trials. The intensive cash burn associated with drug development means that the company may need to secure additional financing, potentially through selling new shares, which could dilute the value for existing stockholders. Failure to raise necessary capital on favorable terms could force Olema to delay or discontinue critical development programs, directly impacting its future growth and valuation.
AI Analysis | Feedback
Major pharmaceutical companies are developing advanced oral selective estrogen receptor degrader (SERD) therapies for ER-positive, HER2-negative breast cancer that are significantly further along in clinical development than Olema's lead candidate, OP-1250. For instance, oral SERDs such as Arvinas/Pfizer's vepdegestrant, Eli Lilly's imoventant, and Roche's giredestrant are currently in Phase 3 clinical trials, while OP-1250 is in Phase 1/2. Should these competitors successfully complete their pivotal trials and gain regulatory approval, they could establish a dominant market position for oral SERDs, potentially limiting the future market opportunity and commercial viability for OP-1250.
AI Analysis | Feedback
Olema Pharmaceuticals (NASDAQ: OLMA) is developing OP-1250 (palazestrant), an estrogen receptor (ER) antagonist and selective ER degrader for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. The addressable market for ER-positive, HER2-negative breast cancer is significant. In the United States, the total market size for ER+/HER2- breast cancer was estimated at USD 6,759 million in 2022 and is projected to grow through 2036. Globally, the HER2-negative breast cancer market was valued at approximately US$14.4 billion in 2024 and is projected to reach US$21.5 billion by 2030. Hormone receptor-positive/HER2-negative tumors constituted 57.25% of the HER2-negative breast cancer market size in 2025. Based on these figures, the global market for hormone receptor-positive/HER2-negative breast cancer was approximately USD 8.24 billion in 2025 (calculated as 57.25% of US$14.4 billion). OP-1250 specifically targets the recurrent, locally advanced, or metastatic forms within this broader ER+/HER2- breast cancer market. While a precise market size solely for this advanced stage sub-segment is not available, the figures for the overall ER+/HER2- breast cancer market indicate the significant scope of the disease area.AI Analysis | Feedback
Olema Pharmaceuticals (OLMA), a clinical-stage biopharmaceutical company focused on women's cancers, is poised for potential revenue growth over the next two to three years primarily through the successful advancement of its lead product candidates and strategic collaborations. While the company is currently pre-revenue from product sales, anticipated revenue drivers include:- Successful Advancement and Potential Regulatory Milestones for Palazestrant (OP-1250): The most significant driver of future revenue growth for Olema Pharmaceuticals is the successful progression of its lead product candidate, palazestrant (OP-1250), through pivotal Phase 3 clinical trials and towards potential regulatory approval. Top-line data from the Phase 3 OPERA-01 monotherapy study is anticipated in the second half of 2026, which is a critical catalyst for validating the drug's potential. Additionally, the Phase 3 OPERA-02 trial, evaluating palazestrant in combination with ribociclib, is actively enrolling patients. Positive outcomes from these trials and the subsequent submission of a New Drug Application (NDA) to the FDA for potential approval, with preparations for a possible commercial launch set for late 2027, are crucial for future product-based revenue.
- Strategic Partnerships and Collaborations: Olema Pharmaceuticals has demonstrated a strategy of forging significant collaborations to advance its pipeline. The company has a collaboration with Novartis for the Phase 3 OPERA-02 trial. Such strategic partnerships can provide substantial upfront payments, research funding, and milestone payments upon the achievement of specific clinical, regulatory, or commercial goals. These payments are a key source of revenue for clinical-stage biopharmaceutical companies like Olema. There is also mention of a potential collaboration with Pfizer and an ongoing Phase 1b/2 study with atirmociclib.
- Progression of OP-3136 and Pipeline Expansion: Beyond palazestrant, the advancement of other pipeline candidates, such as OP-3136 (a potent lysine acetyltransferase 6 (KAT6) inhibitor), represents another potential driver of future revenue. Initial clinical results for OP-3136 are expected in the second quarter of 2026. Successful development of additional assets can broaden the company's therapeutic portfolio, enhance its attractiveness for new partnerships, and potentially lead to new revenue streams through licensing agreements or future product sales.
AI Analysis | Feedback
Share Repurchases
No information available regarding share repurchases made or authorized by Olema Pharmaceuticals over the last 3-5 years.
Share Issuance
- In November 2025, Olema Pharmaceuticals closed a public offering of 11,500,000 shares of common stock, including the full exercise of the underwriters' option, resulting in gross proceeds of approximately $218.5 million.
- Olema Pharmaceuticals completed an equity private placement in December 2024, raising approximately $250 million.
- In January 2025, the company entered into agreements to exchange approximately 6,070,000 shares of its common stock for pre-funded warrants with Bain Capital, Paradigm BioCapital, and BVF Partners.
Inbound Investments
- Olema Pharmaceuticals secured a $250 million private placement in December 2024 with new and existing institutional and accredited investors, including Bain Capital Life Sciences and other firms, to fund its clinical endeavors.
- The company forged a significant collaboration with Novartis in December 2024 to advance its pivotal Phase 3 OPERA-02 trial, combining palazestrant with ribociclib.
- In November 2025, Olema Pharmaceuticals announced a new clinical trial agreement with Pfizer to evaluate palazestrant in combination with atirmociclib.
Outbound Investments
No information available regarding outbound investments made by Olema Pharmaceuticals over the last 3-5 years.
Capital Expenditures
- Olema Pharmaceuticals' net loss of $162.5 million in 2025 was primarily driven by $178.7 million in operating expenses, reflecting increased research and development (R&D) and clinical trial spending.
- GAAP R&D expenses increased to $157.7 million for the full year 2025, up from $124.5 million in 2024 and $86.1 million in 2023, mainly due to increased spending on clinical operations and development activities for palazestrant and OP-3136.
- In the second quarter of 2025, GAAP R&D expenses included a one-time milestone payment of $10 million made to Aurigene.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Olema Pharmaceuticals Earnings Notes | 12/27/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to OLMA.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | PGNY | Progyny | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 03272026 | CNC | Centene | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -0.6% |
| 03272026 | OSCR | Oscar Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.0% | 3.0% | -2.6% |
| 03202026 | WAT | Waters | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -0.4% | -0.4% | -3.3% |
| 03202026 | GILD | Gilead Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.6% | 1.6% | -2.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 13.65 |
| Mkt Cap | 1.1 |
| Rev LTM | 54 |
| Op Inc LTM | -105 |
| FCF LTM | -111 |
| FCF 3Y Avg | -105 |
| CFO LTM | -111 |
| CFO 3Y Avg | -105 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 0.1% |
| Rev Chg 3Y Avg | 18.2% |
| Rev Chg Q | -86.8% |
| QoQ Delta Rev Chg LTM | -18.6% |
| Op Mgn LTM | -74.7% |
| Op Mgn 3Y Avg | -179.6% |
| QoQ Delta Op Mgn LTM | -23.6% |
| CFO/Rev LTM | -77.9% |
| CFO/Rev 3Y Avg | -162.8% |
| FCF/Rev LTM | -78.3% |
| FCF/Rev 3Y Avg | -165.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.1 |
| P/S | 11.0 |
| P/EBIT | -6.9 |
| P/E | -8.7 |
| P/CFO | -6.4 |
| Total Yield | -11.5% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -18.3% |
| D/E | 0.0 |
| Net D/E | -0.3 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 9.2% |
| 3M Rtn | 3.6% |
| 6M Rtn | 36.2% |
| 12M Rtn | 94.0% |
| 3Y Rtn | -24.5% |
| 1M Excs Rtn | 4.2% |
| 3M Excs Rtn | 5.0% |
| 6M Excs Rtn | 30.6% |
| 12M Excs Rtn | 78.2% |
| 3Y Excs Rtn | -98.6% |
Price Behavior
| Market Price | $16.30 | |
| Market Cap ($ Bil) | 1.5 | |
| First Trading Date | 11/19/2020 | |
| Distance from 52W High | -54.5% | |
| 50 Days | 200 Days | |
| DMA Price | $19.38 | $15.16 |
| DMA Trend | up | down |
| Distance from DMA | -15.9% | 7.5% |
| 3M | 1YR | |
| Volatility | 81.0% | 162.5% |
| Downside Capture | 0.58 | -0.77 |
| Upside Capture | -228.32 | 62.52 |
| Correlation (SPY) | 11.0% | -0.1% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.89 | 0.71 | 0.80 | -0.79 | 0.06 | 0.82 |
| Up Beta | 3.06 | 2.36 | 1.21 | 1.95 | 0.81 | 1.04 |
| Down Beta | 1.97 | 2.05 | 1.03 | -0.85 | -0.27 | 0.24 |
| Up Capture | -454% | -235% | -101% | -18% | 42% | 222% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 5 | 16 | 25 | 54 | 123 | 376 |
| Down Capture | 259% | 167% | 171% | -189% | -193% | 98% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 17 | 26 | 38 | 72 | 128 | 365 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OLMA | |
|---|---|---|---|---|
| OLMA | 390.8% | 162.6% | 1.51 | - |
| Sector ETF (XLV) | 11.9% | 16.0% | 0.52 | 17.2% |
| Equity (SPY) | 24.2% | 12.9% | 1.49 | 0.3% |
| Gold (GLD) | 53.4% | 27.6% | 1.55 | 1.6% |
| Commodities (DBC) | 26.8% | 16.2% | 1.47 | -2.2% |
| Real Estate (VNQ) | 18.7% | 13.8% | 1.00 | 11.3% |
| Bitcoin (BTCUSD) | -6.8% | 42.9% | -0.05 | 7.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OLMA | |
|---|---|---|---|---|
| OLMA | -11.1% | 108.3% | 0.34 | - |
| Sector ETF (XLV) | 6.6% | 14.6% | 0.27 | 22.2% |
| Equity (SPY) | 11.1% | 17.0% | 0.50 | 18.9% |
| Gold (GLD) | 22.5% | 17.8% | 1.03 | 6.1% |
| Commodities (DBC) | 11.7% | 18.8% | 0.51 | 1.4% |
| Real Estate (VNQ) | 3.9% | 18.8% | 0.11 | 20.0% |
| Bitcoin (BTCUSD) | 5.8% | 56.5% | 0.32 | 12.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OLMA | |
|---|---|---|---|---|
| OLMA | -10.2% | 107.4% | 0.27 | - |
| Sector ETF (XLV) | 9.9% | 16.5% | 0.49 | 21.2% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 18.4% |
| Gold (GLD) | 14.3% | 15.9% | 0.75 | 6.4% |
| Commodities (DBC) | 8.8% | 17.6% | 0.42 | 0.9% |
| Real Estate (VNQ) | 5.4% | 20.7% | 0.23 | 19.5% |
| Bitcoin (BTCUSD) | 67.7% | 66.9% | 1.07 | 12.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/10/2025 | 4.2% | 0.6% | 267.4% |
| 8/11/2025 | 16.2% | 26.0% | 70.9% |
| 3/18/2025 | -0.7% | 1.2% | 2.9% |
| 11/12/2024 | -0.5% | -24.4% | -41.8% |
| 8/6/2024 | -9.9% | -10.1% | -15.1% |
| 3/11/2024 | -6.6% | -14.8% | -15.8% |
| 11/7/2023 | 3.1% | -4.5% | -29.8% |
| 8/8/2023 | 12.1% | 14.3% | 21.1% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 8 | 6 |
| # Negative | 7 | 8 | 10 |
| Median Positive | 4.9% | 3.2% | 46.0% |
| Median Negative | -6.6% | -12.4% | -21.0% |
| Max Positive | 16.2% | 26.0% | 267.4% |
| Max Negative | -26.7% | -36.7% | -61.8% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/16/2026 | 10-K |
| 09/30/2025 | 11/10/2025 | 10-Q |
| 06/30/2025 | 08/11/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/18/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 03/11/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/09/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| 03/31/2022 | 05/09/2022 | 10-Q |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Harmon, Cyrus | Direct | Sell | 12292025 | 28.53 | 2,881 | 82,195 | 21,148,119 | Form | |
| 2 | Clark, Ian T | Direct | Sell | 12232025 | 29.73 | 264,800 | Form | |||
| 3 | Myles, David C | CH. DISCOV. & NON-CLIN DEV OFF | Direct | Sell | 12232025 | 30.46 | 51,000 | 1,553,544 | 16,811,199 | Form |
| 4 | Zojwalla, Naseem | Chief Medical Officer | Direct | Sell | 12232025 | 28.20 | 70,000 | 1,973,729 | 2,932,313 | Form |
| 5 | Zojwalla, Naseem | Chief Medical Officer | Direct | Sell | 12232025 | 28.04 | 100,000 | 2,804,000 | 1,514,076 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.